File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fphar.2020.587526
- Scopus: eid_2-s2.0-85101976604
- PMID: 33519448
- WOS: WOS:000612205700001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis
Title | Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis |
---|---|
Authors | |
Keywords | public-private partnership pharmaceutical industry drug discovery patient-centered innovation intellectual property |
Issue Date | 2021 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology |
Citation | Frontiers in Pharmacology, 2021, v. 11, p. article no. 587526 How to Cite? |
Abstract | Open innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining social media attention remains largely unexplored. The scientific literature of open innovation was examined by means of bibliometric analyses to identify the most prolific authors, organizations, countries, journals, research areas, and recurring terms. By accessing the Web of Science Core Collection and Altmetric electronic databases, citation-related and Altmetric data were evaluated. Public-private partnerships and a selection of newly introduced potential novel drugs in the analyzed publications were identified. North America and Europe were the major literature contributors. Research outputs were mainly published in journals focused on business and economics, pharmacology and pharmacy, and engineering. Many pharmaceutical and biotechnological companies contributed to the analyzed publications, with higher mean citation counts and social media attention (Altmetric score) than nonindustry articles. Public-private partnerships fostered financial support, sharing of expertise and intellectual property, and research collaborations. In summary, open innovation might serve as a powerful strategy to both benefit the involved industry entities and accelerate the development of solutions and products for the betterment of human health. |
Persistent Identifier | http://hdl.handle.net/10722/295513 |
ISSN | 2023 Impact Factor: 4.4 2023 SCImago Journal Rankings: 1.066 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yeung, AWK | - |
dc.contributor.author | Atanasov, AGA | - |
dc.contributor.author | Sheridan, H | - |
dc.contributor.author | Klager, E | - |
dc.contributor.author | Eibensteiner, F | - |
dc.contributor.author | Völkl-Kernsock, S | - |
dc.contributor.author | Kletecka-Pulker, M | - |
dc.contributor.author | Willschke, H | - |
dc.contributor.author | Schaden, E | - |
dc.date.accessioned | 2021-01-25T11:15:57Z | - |
dc.date.available | 2021-01-25T11:15:57Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Frontiers in Pharmacology, 2021, v. 11, p. article no. 587526 | - |
dc.identifier.issn | 1663-9812 | - |
dc.identifier.uri | http://hdl.handle.net/10722/295513 | - |
dc.description.abstract | Open innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining social media attention remains largely unexplored. The scientific literature of open innovation was examined by means of bibliometric analyses to identify the most prolific authors, organizations, countries, journals, research areas, and recurring terms. By accessing the Web of Science Core Collection and Altmetric electronic databases, citation-related and Altmetric data were evaluated. Public-private partnerships and a selection of newly introduced potential novel drugs in the analyzed publications were identified. North America and Europe were the major literature contributors. Research outputs were mainly published in journals focused on business and economics, pharmacology and pharmacy, and engineering. Many pharmaceutical and biotechnological companies contributed to the analyzed publications, with higher mean citation counts and social media attention (Altmetric score) than nonindustry articles. Public-private partnerships fostered financial support, sharing of expertise and intellectual property, and research collaborations. In summary, open innovation might serve as a powerful strategy to both benefit the involved industry entities and accelerate the development of solutions and products for the betterment of human health. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology | - |
dc.relation.ispartof | Frontiers in Pharmacology | - |
dc.rights | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | public-private partnership | - |
dc.subject | pharmaceutical industry | - |
dc.subject | drug discovery | - |
dc.subject | patient-centered innovation | - |
dc.subject | intellectual property | - |
dc.title | Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis | - |
dc.type | Article | - |
dc.identifier.email | Yeung, AWK: ndyeung@hku.hk | - |
dc.identifier.authority | Yeung, AWK=rp02143 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fphar.2020.587526 | - |
dc.identifier.pmid | 33519448 | - |
dc.identifier.pmcid | PMC7840485 | - |
dc.identifier.scopus | eid_2-s2.0-85101976604 | - |
dc.identifier.hkuros | 320998 | - |
dc.identifier.volume | 11 | - |
dc.identifier.spage | article no. 587526 | - |
dc.identifier.epage | article no. 587526 | - |
dc.identifier.isi | WOS:000612205700001 | - |
dc.publisher.place | Switzerland | - |